ClinicalTrials.gg
RecruitingNCT04994015Updated Sep 8, 2026

Parkinson's Foundation PD GENEration Genetic Registry

An observational study in Parkinson's Disease, sponsored by Parkinson's Foundation. Recruiting at 70 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Parkinson's Foundation · Observational

How we know

From the registry’s dates

  • Started Dec 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
35,382
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
6th of 379
35,382 · median 78
Started
2020
with 89 others
Observational
381 of 1,650
75 open now
Primary completion
2027-07
later than 188 of 384 live
Registered
1,190th of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 6th largest by planned enrollment of the 379 observational ones that give a count, is one of 90 that started in 2020, is one of 381 observational ones, reaches primary completion later than 188 of the 384 other live ones, and was the 1,190th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

Development of a central repository for PD-related genomic data for future research.

Read the detailed description

The purpose of this study is to develop a central repository for PD-related genomic data by individuals who consent to deposit their data and bank their residual DNA obtained through clinical genetic testing for future research use.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Genetics
  • Genetic Counseling
  • Whole Genome Sequencing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any person with probable diagnosis of Parkinson's disease according to the Movement Disorders Society criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study Population 1: PWP (open for recruitment)

    1. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease: probable diagnosis.
    2. Willingness to undergo genetic testing, and choose to be informed of genetic testing results for GBA, LRRK2 and 5 additional PD related genes (SNCA, VPS35, PRKN, PINK-1, PARK7).
    3. Capacity to give full in writing or electronically, and have read and signed the informed consent forms (ICFs) based on site clinician's determination.
    4. Able to perform study activities (including completion of either online, in-person or paper surveys).

Study Population 2: People at risk of developing PD (not open for recruitment)

1. Family members of Study Population 1 may be invited to participate in the study if confirmatory genetic testing is deemed necessary by the genetic testing laboratory.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome), including that due to medications, metabolic disorders, encephalitis, cerebrovascular disease, or normal pressure hydrocephalus.
  2. Individuals who have received a blood transfusion within the past 3 months.
  3. Individuals who have active hematologic such as lymphoma or leukemia.
  4. Individuals who have had a bone marrow transplant within the past 5 years.
  5. Under the age of 18
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
35,382 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes
Biospecimen retention
Samples with dna

Interventions

  • DeviceLab Assay for seven genetic variants for Parkinson's Disease

    Counseling provided to participant by site clinician/physician/genetic counselor.

06

What researchers measure

Primary outcomes

  1. Prevalence of Parkinson's related genetic mutations in an convenience cohort

    Identify people with Parkinson's who have genetic mutations to advance basic science and clinical research.

    Time frame: 6 months

  2. Educating people with Parkinson's of their genetic mutation status through genetic testing and counseling

    People who are informed of their genetic status may be empowered to learn more about their disease and participant in clinical research.

    Time frame: 6 months

07

Study locations

56 of 70 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2020 (actual). Primary completion is estimated for Jul 2027, 78 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Aug 6, 2021
StartActual
Dec 20, 2020
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04994015
Lead sponsor
Parkinson's Foundation
Collaborators
Indiana University, Fulgent Genetics, The Parkinson Study Group
Responsible party
Sponsor
First posted
Aug 6, 2021
Start date
Dec 20, 2020
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Kamalini Ghosh, MS
Contact
kghosh@parkinson.org
1-800-473-4636
James Beck, PhD
principal investigator · Parkinson's Foundation
Roy N Alcalay, MS, MD
principal investigator · Tel Aviv Sourasky Medical Center, Columbia University Irving Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion